10 results
8-K
EX-99.3
IVVD
Invivyd Inc
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
AND OPEN LABEL, COMPRISES OLDER MEDICALLY COMPLEX SUBJECTS Parameter Cohort A (N=306) Cohort B (N=479) Gender 61% female; 39% male 53% female; 47% male
DEF 14A
IVVD
Invivyd Inc
10 Apr 23
Definitive proxy
4:07pm
27, 2023)
Total Number of Directors
Female
Male
Non-
Binary
Did Not
Disclose
Gender
Part I: Gender Identity
Directors
Part II: Demographic … diversity of race, ethnicity, gender, age, education, cultural background, skills, and other factors as it deems appropriate, given the current needs of our
PRE 14A
IVVD
Invivyd Inc
31 Mar 23
Preliminary proxy
4:36pm
Non-
Binary
Did Not
Disclose
Gender
Part I: Gender Identity
Directors
Part II: Demographic Background
African American or Black
Alaskan Native … of diversity and inclusion and, accordingly, in conducting this assessment, our Board considers diversity of race, ethnicity, gender, age, education
S-3
EX-4.4
IVVD
Invivyd Inc
28 Sep 22
Shelf registration
5:08pm
defined in this Article have the meanings assigned to them in this Article and include the plural as well as the singular and the masculine gender shall
DEFC14C
g1fwx0mmf86n ph
2 Jun 22
Information statement in contested solicitation
4:24pm
PRER14C
0mz3 lv69r1j
31 May 22
Preliminary revised information
5:09pm
PREC14C
rh19 kbljsefk7vofk
19 May 22
Preliminary information statement in contested solicitation
5:05pm
10-K/A
eyasal74bcm gdd
29 Apr 22
Annual report (amended)
4:43pm
PREC14A
iz51xaapsiihg
26 Apr 22
Preliminary proxy with contested solicitation
8:48am
- Prev
- 1
- Next